Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > German drugmakers lobby says US price rules will challenge domestic market

German drugmakers lobby says US price rules will challenge domestic market

Published by Global Banking & Finance Review®

Posted on February 11, 2026

1 min read

Last updated: February 11, 2026

German drugmakers lobby says US price rules will challenge domestic market - Finance news and analysis from Global Banking & Finance Review

Tags:innovation healthcare insurance financial community financial markets

Quick Summary

US drug price regulations may lead to higher prices or delayed launches in Germany, warns Pharma Deutschland, urging government action.

German Pharma Lobby Warns US Price Regulations May Impact Market

Impact of US Drug Price Regulations on Germany

FRANKFURT, Feb 11 (Reuters) - One of Germany's leading pharma industry lobby groups has warned that new drug price regulation in the United States could prompt companies to demand higher prices of new drugs in Germany or else shun a launch there.

Concerns from Pharma Deutschland

In a statement on Wednesday, the Pharma Deutschland association, which counts 400 member companies, said that drugmakers active in both nations would have to re-evaluate their pricing and launch strategies.

Potential Delays in Medicine Launches

As a result, "Germany could fall behind or miss out entirely when it comes to the introduction of new medicines", it added.

Government Response Required

"Innovative medicines could be launched later or not at all in Germany or in Europe in order to avoid low price references and to protect pricing in the U.S." said Dorothee Brakmann, the lobby group's managing director.

She added the German government and the country's health system would have to respond to the challenge.

(Reporting by Ludwig Burger, Editing by Miranda Murray)

Key Takeaways

•US drug price regulations may lead to higher prices in Germany.
•Pharma Deutschland warns of potential delays in medicine launches.
•German government urged to respond to pricing challenges.
•New regulations could affect drug launch strategies in Germany.
•German market might miss out on innovative medicines.

Frequently Asked Questions about German drugmakers lobby says US price rules will challenge domestic market

1What is a pharmaceutical lobby?

A pharmaceutical lobby is a group of organizations or individuals that advocate for the interests of the pharmaceutical industry, influencing legislation and public policy.

2What is the impact of pricing strategies on drug launches?

Pricing strategies can significantly affect drug launches, as companies may delay or avoid launching products in markets where prices are regulated or deemed too low.

Impact of US Drug Price Regulations on Germany

Concerns from Pharma Deutschland

Potential Delays in Medicine Launches

As a result, "Germany could fall behind or miss out entirely when it comes to the introduction of new medicines", it added.

Government Response Required

She added the German government and the country's health system would have to respond to the challenge.

(Reporting by Ludwig Burger, Editing by Miranda Murray)

Key Takeaways

•US drug price regulations may lead to higher prices in Germany.

•Pharma Deutschland warns of potential delays in medicine launches.

•German government urged to respond to pricing challenges.

•New regulations could affect drug launch strategies in Germany.

•German market might miss out on innovative medicines.

Frequently Asked Questions

1What is a pharmaceutical lobby?

A pharmaceutical lobby is a group of organizations or individuals that advocate for the interests of the pharmaceutical industry, influencing legislation and public policy.

2What is the impact of pricing strategies on drug launches?

Pricing strategies can significantly affect drug launches, as companies may delay or avoid launching products in markets where prices are regulated or deemed too low.